<DOC>
	<DOCNO>NCT00004159</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I/II trial study effectiveness gemcitabine plus paclitaxel treating patient advance non-small cell lung cancer solid tumor .</brief_summary>
	<brief_title>Gemcitabine Plus Paclitaxel Treating Patients With Advanced Non-small Cell Lung Cancer Other Solid Tumor</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose dose limit toxicity biweekly administration gemcitabine paclitaxel patient advance non-small cell lung cancer ( NSCLC ) solid tumor . II . Determine response rate , duration response , disease free interval patient population therapy . OUTLINE : This dose escalation study . Patients receive paclitaxel IV 1 hour follow 2 hour later gemcitabine IV 30 minute day 1 , 15 , 29 . Treatment repeat every 6 week maximum 8 course . Cohorts 3-5 patient receive escalate dos paclitaxel gemcitabine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 5 patient experience dose limit toxicity . Once MTD reach , additional 14 patient ( chemotherapy naive ) advance NSCLC treat recommended phase II dose . Patients follow every 8 week 6 month . PROJECTED ACCRUAL : A minimum 3 patient accrued phase I portion total 14 patient accrue phase II portion study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Phase I portion ( closed accrual maximum tolerate dose dose limit toxicity determine ) Histologically cytologically confirm advanced nonsmall cell lung cancer ( NSCLC ) solid tumor standard curative treatment exist Phase II portion ( open accrual ) : Histologically proven stage IV NSCLC without prior chemotherapy Measurable evaluable disease No primary brain tumor Brain metastasis allow control radiation stereotactic radiosurgery No lymphoproliferative disease No HIV related malignancy PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL Transaminases great 3 time upper limit normal Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 60 mL/min Cardiovascular : No congestive heart failure Other : Not pregnant nursing Fertile patient must use effective contraception No serious nonmalignant disease No active/uncontrolled infection bleeding ( e.g. , active peptic ulcer disease ) No primary malignancy within past 5 year except nonmelanomatous skin cancer carcinoma situ cervix No allergy Cremophor PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Phase I : No prior paclitaxel gemcitabine At least 3 week since prior chemotherapy recover Phase II : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : At least 3 week since prior radiotherapy recover Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>